Jazz Pharmaceuticals (JAZZ) director receives 1,527-share restricted stock unit grant

Rhea-AI Filing Summary

LOVE TED W reported acquisition or exercise transactions in this Form 4 filing.

Jazz Pharmaceuticals plc director Ted W. Love reported receiving a grant of 1,527 ordinary shares in the form of restricted stock units. The award was made at a price of $0.00 per share, reflecting an equity compensation grant rather than a market purchase.

Each restricted stock unit represents the right to receive one ordinary share if certain conditions are met. The units are scheduled to vest in full on July 24, 2026, subject to Dr. Love’s continuous service and additional plan conditions. Following this grant, he holds 1,527 ordinary shares directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider LOVE TED W

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Ordinary Shares	1,527	$0.00	--

Holdings After Transaction: Ordinary Shares — 1,527 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LOVE TED W

(Last) (First) (Middle)

5TH FL. WATERLOO EXCHANGE

WATERLOO RD

(Street)

DUBLIN 4 L2 D04 E5W7

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Jazz Pharmaceuticals plc [ JAZZ ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/26/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	02/26/2026		A(1)		1,527	A	$0.0	1,527	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These restricted stock units are granted pursuant to the Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on July 24, 2026.

	By: /s/Paz Dizon, as attorney in fact For: Ted W. Love	03/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did JAZZ director Ted W. Love report on this Form 4?

Ted W. Love reported an equity grant of 1,527 restricted stock units of Jazz Pharmaceuticals. Each unit represents a right to receive one ordinary share, awarded at $0.00 per share as director compensation under the company’s non-employee director stock award plan.

How many Jazz Pharmaceuticals (JAZZ) shares are involved in Ted W. Love’s latest award?

The award covers 1,527 restricted stock units, each tied to one ordinary share of Jazz Pharmaceuticals. These units increase his reported direct holdings to 1,527 shares, contingent on vesting conditions being satisfied over the specified service period.

At what price were the Jazz Pharmaceuticals (JAZZ) restricted stock units granted to Ted W. Love?

The restricted stock units were granted at $0.00 per share, indicating a compensation award rather than an open-market purchase. This structure is typical for non-employee director equity grants made under a formal stock award or incentive plan.

When do Ted W. Love’s Jazz Pharmaceuticals (JAZZ) restricted stock units vest?

The 1,527 restricted stock units are scheduled to vest in full on July 24, 2026. Vesting is conditioned on Dr. Love’s continuous service with Jazz Pharmaceuticals and satisfaction of additional terms set out in the non-employee directors stock award plan.

What plan governs the JAZZ restricted stock unit grant reported by Ted W. Love?

The grant was made under Jazz Pharmaceuticals’ 2007 Amended and Restated Non-Employee Directors Stock Award Plan. This plan provides equity-based compensation to non-employee directors, with each restricted stock unit convertible into one ordinary share upon vesting.